Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: BIIL 284 BS

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02265627

Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine, low dose
Drug: Cilobradine, high dose
Drug: Itraconazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02264041

The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ethanolic Solution From HFA134a-MDI - low
Drug: Ethanolic Solution From HFA134a-MDI - medium
Drug: Ethanolic Solution From HFA134a-MDI - high
Drug: Ethanolic Solution From Respimat®

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02264145

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban tablet
Drug: Lefradafiban double chamber sachet
Drug: Pantoprazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264106

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole ER tablet
Drug: Pramipexole IR tablet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264132

Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tamsulosin
Drug: Paroxetine

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264184

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan conventional tablet
Drug: Telmisartan film coated tablet

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02263989

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BEA 2180 BR
Drug: Spiriva
Device: Respimat® A 4
Drug: Methacholine Chloride

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 101

Registration Number: NCT02263976

Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Talsaclidine
Drug: Propranolol

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02264093

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBX 245 CL- fasted
Drug: BIBX 245 CL - fed

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02264197

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy